GSK plc
GSK plc Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
1 of 3 strong
The short version
- GSK expects another year of profitable growth in 2026, confirmed in their guidance. - GSK expects another year of profitable growth, with guidance confirmed during the Q1 2026 results call.
From GSK plc's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- GSK expects another year of profitable growth in 2026, confirmed in their guidance.
- Specialty Medicines sales grew 14% in Q1 and continue to drive overall growth.
- Vaccines, notably Shingrix, contributed significantly with a 20% sales increase in Q1; however, tougher comparators expected later this year in Europe and Japan.
- New product launches like Nucala COPD, Exdensur, and Blenrep show strong momentum and growth potential.
- Pipeline acceleration and BD activities focus on high-potential assets, including COPD, oncology ADCs, and Efimosfermin in MASH.
- HIV portfolio growth continues with a 10% sales increase in Q1 alongside advancements in long-acting regimens.
2 more points from GSK plc's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what GSK plc said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Investments in business development (BD) primarily included a GBP 1.4 billion upfront payment to acquire Rapt Therapeutics.
- In Q2, an expected outflow of $950 million for the acquisition of 35Pharma, whose lead asset HS235 is in Phase I development for pulmonary hypertension.
- Portfolio optimization actions such as the divestment of the Rockville manufacturing site and the out-licensing of linerixibat contributed to capital generation.
- Strategic acquisitions in Q1 included ozureprubart (for food allergies) and HS235 (pulmonary hypertension), both aiming to be best-in-class assets.
- Planning to reinvest cash income from strategic actions and strong cash generation into pipeline acceleration and growth initiatives.
2 more points from GSK plc's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what GSK plc said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- U.S. Shingrix inventory stocking is around 45%, up 3.5 percentage points versus the same time last year, within the typical annual increase range of 2-4 percentage points.
- Wholesaler stocking in Q1 2026 was 0.6 million doses, steady compared to 0.5 million at the end of last year and 0.4 million during the same time last year.
- Retail inventory increased to 2.4 million doses compared to 1.7 million at the same time last year, partly due to the launch of the prefilled syringe (PFS).
- Stocking and inventory build reflect a balance of supply readiness and underlying patient demand, particularly focused on the comorbid population.
Continue your research
Others in Pharmaceuticals this season
- Elanco Animal Health Incorporated (Q2 FY26)
Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S
- Axsome Therapeutics, Inc. (Q2 FY26)
Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from
- Jazz Pharmaceuticals plc (Q2 FY26)
Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo
- Viatris Inc. (Q2 FY26)
Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
GSK plc and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were GSK plc Q2 FY26 results?
- GSK expects another year of profitable growth in 2026, confirmed in their guidance. - GSK expects another year of profitable growth, with guidance confirmed during the Q1 2026 results call.
What is GSK plc share price analysis?
GSK plc currently shows a below-average growth signal. The stock trades at a P/E of 13.4 with a market cap of $104,500. Investors should review the full earnings analysis for detailed insights.
Is GSK plc planning capital expenditure?
- Investments in business development (BD) primarily included a GBP 1.4 billion upfront payment to acquire Rapt Therapeutics.
Keep GSK plc on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.